The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 49-55

  Kosaka, Hiromichi ^a   Hirayama, Kazunori ^a   Yoda, Nobuyuki ^a   Sasaki, Katsutoshi ^a   Kitayama, Tetsuya ^a   Kusaka, Hideaki ^a   Matsubara, Masahiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Aldosterone; Benidipine; Calcium channel blocker; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; AMLODIPINE; AZELNIDIPINE; BENIDIPINE; EFONIDIPINE; EPLERENONE; MINERALOCORTICOID RECEPTOR; NIMODIPINE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING COMPETITION; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYPERTENSION; IC 50; LIGAND BINDING; MOLECULAR DOCKING; PLEIOTROPY; PRIORITY JOURNAL;

ALDOSTERONE; BINDING SITES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CALCIUM CHANNELS, T-TYPE; CELL LINE; DIHYDROPYRIDINES; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PYRIDINES; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STEREOISOMERISM;

EID: 77952322018     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.018     Document Type: Article

References (32)

1. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol. 2008, 584:424-434.
2. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
3. Bledsoe R.K., Madauss K.P., Holt J.A., Apolito C.J., Lambert M.H., Pearce K.H., Stanley T.B., Stewart E.L., Trump R.P., Willson T.M., Williams S.P. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J. Biol. Chem. 2005, 280:31283-31293.
4. Dietz J.D., Du S., Bolten C.W., Payne M.A., Xia C., Blinn J.R., Funder J.W., Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.
5. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998, 17:3317-3325.
6. Furukawa T., Yamakawa T., Midera T., Sagawa T., Mori Y., Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1999, 291:464-473.
7. 2+ channels. Br. J. Pharmacol. 2004, 143:1050-1057.
8. 2+ channel (alpha1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. 2005, 45:241-246.
9. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Lifton R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
10. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
11. Hayashi K., Ozawa Y., Fujiwara K., Wakino S., Kumagai H., Saruta T. Role of actions of calcium antagonists on efferent arterioles-with special references to glomerular hypertension. Am. J. Nephrol. 2003, 23:229-244.
12. Hellal-Levy C., Fagart J., Souque A., Rafestin-Oblin M.E. Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int. 2000, 57:1250-1255.
13. Hultman M.L., Krasnoperova N.V., Li S., Du S., Xia C., Dietz J.D., Lala D.S., Welsch D.J., Hu X. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol. Endocrinol. 2005, 19:1460-1473.
14. Imagawa K., Okayama S., Takaoka M., Kawata H., Naya N., Nakajima T., Horii M., Uemura S., Saito Y. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J. Cardiovasc. Pharmacol. 2006, 47:133-138.
15. 3H-nitrendipine binding sites. Arzneimittelforschung 1988, 38:1681-1683.
16. Kawata T., Hashimoto S., Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1997, 30:431-436.
17. 2+ channel blocker with a cardioprotective effect. Cardiovasc. Drug Rev. 1999, 17:1-15.
18. Li Y., Suino K., Daugherty J., Xu H.E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell 2005, 19:367-380.
19. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
20. Marney A.M., Brown N.J. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 2007, 113:267-278.
21. Masumoto K., Takeyasu A., Oizumi K., Kobayashi T. Studies of novel 1, 4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC). Yakugaku Zasshi 1995, 115:213-220.
22. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 1998, 10:384-391.
23. Muto K., Kuroda T., Kawato H., Karasawa A., Kubo K., Nakamizo N. Synthesis and pharmacological activity of stereoisomers of 1, 4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester. Arzneimittelforschung 1988, 38:1662-1665.
24. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
25. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
26. Sasaki K., Watanabe E., Kawashima K., Sekine S., Dohi T., Oshima M., Hanai N., Nishi T., Hasegawa M. Expression cloning of a novel Gal beta (1-3/1-4) GlcNAc alpha 2, 3-sialyltransferase using lectin resistance selection. J. Biol. Chem. 1993, 268:22782-22787.
27. Sherman W., Day T., Jacobson M.P., Friesner R.A., Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49:534-553.
28. Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Res. 2004, 61:663-670.
29. Weinberger M.H. Eplerenone: a new selective aldosterone receptor antagonist. Drugs Today (Barc.) 2004, 40:481-485.
30. Yao K., Nagashima K., Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J. Pharmacol. Sci. 2006, 100:243-261.
31. Young M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2008, 17:174-180.
32. Yue W., Kimura S., Fujisawa Y., Tian R., Li F., Rahman M., Nishiyama A., Fukui T., Abe Y. Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens. Res. 2001, 24:429-436.